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Proline- and acid-rich (PAR) basic region leucine zipper
(bZIP) proteins thyrotroph embryonic factor (TEF), D-site-
binding protein (DBP), and hepatic leukemia factor have been
involved in neurotransmitter homeostasis and amino acid
metabolism. Here we demonstrate a novel role for these pro-
teins in the transcriptional control of a BH3-only gene. PAR
bZIP proteins are able to transactivate the promoter of bcl-gS.
This promoter is particularly responsive toTEF activation and is
silencedbyNFIL3, a repressor that shares the consensus binding
site with PAR bZIP proteins. Consistently, transfection of TEF
induces the expression of endogenous bcl-gS in cancer cells, and
this induction is independent of p53. A naturally occurring var-
iant of DBP (tDBP), lacking the transactivation domain, has
been identified and shown to impede the formation of active
TEF dimers in a competitive manner and to reduce the TEF-de-
pendent induction of bcl-gS. Of note, treatment of cancer cells
with etoposide inducesTEFactivation andpromotes the expres-
sion of bcl-gS. Furthermore, blockade of bcl-gS or TEF expres-
sion by a small interfering RNA strategy or transfection with
tDBP significantly reduces the etoposide-mediated apoptotic
cell death. These findings represent the first described role for
PAR bZIP proteins in the regulation of a gene involved in the
execution of apoptosis.
Two genes, cell death specification protein 1 (ces-1) and
ces-2, control the decisions of neuro-secretorymotor sister cells
in Caenorhabditis elegans to undergo apoptosis. A genetic
approach showed that these factors regulate the genes required
for apoptosis and that a gain of ces-1 function or a reduction of
ces-2 function prevents these cells from dying (1). The pro-apo-
ptotic CES-2 protein negatively regulates CES-1, which pre-
vents the death of the neuro-secretory motor sister cells by
transcriptional silencing of Egl-1, a BH3-only protein required
for apoptosis inC. elegans (2, 3). CES-2 is similar tomembers of
the proline- and acid-rich (PAR)4 subfamily of basic region
leucine zipper (bZIP) transcription factors, and both share the
DNA binding specificity (4).
Mammalian homologs of CES-2 include thyrotroph embry-
onic factor (TEF), albumin D-site-binding protein (DBP), and
hepatic leukemia factor (HLF) (5–7). These PAR bZIP proteins
have recently been shown to be involved in amino acid and
neurotransmitter metabolism through transcriptome profiling
analyses in both liver and brain (8). Thus, despite the pro-apo-
ptotic activity described for CES-2 promoting the induction
of Egl-1 through an indirect pathway, none of its human
homologs have been associated with the transcriptional regu-
lation of BH3-only genes or other executors of apoptosis.
BH3-only proteins are a pro-apoptotic subgroup of the Bcl-2
family of apoptosis regulators, which share only the short BH3
region with the rest of the family (9). Genetic experiments have
shown that these proteins are essential initiators of pro-
grammed cell death in species as distantly related as mice and
C. elegans. They are regulated transcriptionally and by post-
translational modifications such as phosphorylation, ubiquiti-
nation, and proteolytic cleavage (10–13). BH3-only proteins
include Bid, Bad, Bim, Puma, Noxa, Hrk, Bik, Bmf, Bnip3, and
Bnip3L (14, 15). Another member, Bcl-gS, the short splice var-
iant of the bcl-g gene, which is uniquely expressed in testis, has
recently joined this list (16). BH3-only proteins serve as
upstream sentinels that selectively respond to apoptotic stimuli
inducing activation of other members, mainly bax and bak,
required for execution of cell death (17). Blockade of expression
or activation of different BH3-only proteins has been associated
with cancer cell survival. To this end, Hrk ismethylated in colo-
rectal and gastric cancer cell lines, which correlates with loss of
expression of this proapoptotic gene. Restoration of Hrk pro-
motes apoptosis and enhances adriamycin-induced cell death
(18).We previously described that Hrk expression is silenced in
hematopoietic progenitors by a growth factor-dependent tran-
scriptional repressor mechanism that avoids inappropriate
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apoptosis in these cells (19). Blockade of other BH3-only genes
such as Noxa or Bim also promotes resistance to chemothera-
peutic agents in different tumor cell models (20, 21). Therefore,
inactivation or transcriptional repression of BH3-only proteins
may represent an advantage for tumor cells to escape chemo-
therapy-induced apoptosis, and consequently, deciphering the
regulation of these genes is crucial to understand the mecha-
nism by which they contribute to cell fate.
We report here a novel transcriptional pathway, mediated by
PAR bZIP proteins, mainly TEF, that promotes the expression
of a BH3-only gene. TEF binds to a consensus site in the pro-
moter region of bcl-gS and induces its expression. bcl-gS is up-
regulated by transfection of tumor cells with TEF or drastically
reduced byNFIL3, a putative antagonist of PAR bZIP proteins, or
by a dominant negative isoform of DBP. Additionally, the TEF-
bcl-gS transcriptional pathway can be triggered by chemothera-
peutic agents andmediates in part the apoptotic response. This is
the firstdescriptionofPARbZIP transcription factors that activate
the expression of a BH3-only gene.
EXPERIMENTAL PROCEDURES
Cells—Human embryonal carcinoma cell line NTERA-2 and
HEK293T cells weremaintained inDulbecco’smodified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf serum
(Flow Laboratories, Irvine, CA). Colorectal carcinoma cells
HCT116 and their p53 (/) derivatives (22), a gift from B.
Vogelstein, were grown in McCoy’s 5A medium (Invitrogen)
supplemented with 10% fetal calf serum. In some experiments,
cells were treated with the indicated concentrations of etopo-
side or cisplatin (Sigma).
Antibody Production—TEF cDNA was cloned into NdeI and
XhoI sites of the pET30b expression vector (Novagen,Madison,
WI), and this construct was used for transformation of
BL21pLysS bacteria (Stratagene, La Jolla, CA). Expression of
TEF was induced by treating cells with 1 mM isopropyl--D-
thiogalactopyranosid, and the recombinant protein was puri-
fied by using the nickel-nitrilotriacetic acid spin kit (Qiagen,
Hilden, Germany). C57BL/6 mice were immunized subcutane-
ously with 50 g of the purified protein emulsified 1:1 in com-
plete Freund’s adjuvant. After 21 days, the mice were boosted
with the same amount of protein, and by day 35, blood was
collected, and the serum was tested for the presence of TEF-
specific antibodies.
Analysis of Apoptosis—Apoptosis was assessed by an
enzyme-immunoassay method that quantifies the histone-as-
sociated DNA fragments present in the cytosol (Roche Applied
Science, Mannheim, Germany) as described previously (23).
Values were represented as the percentage of apoptosis with
respect to a positive internal control. Apoptosis was also con-
firmed by using a flow cytometry analysis with an active caspase
9 staining kit (MBL Int., Woburn, MA).
Electrophoretic Mobility Shift Assay (EMSA)—Cells were
lysed, andnuclear fractionswere resuspended in 20mMHEPES,
pH 7.9, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 20%
glycerol. Nuclear extracts (5–10 g of total protein) were incu-
bated with a 32P-labeled double-stranded DNA probe from the
promoter region of bcl-gS (5-CAGATACATAAGCA-3).
Samples were run on a 5% non-denaturing polyacrylamide gel
in 200 mM Tris borate, 2 mM EDTA. Gels were dried and visu-
alized by autoradiography. Supershifts were performed using
monoclonal antibodies specific for FLAG (Sigma) andMyc (BD
Biosciences) tags.
Analyses of RNA—Total RNAwas prepared usingTRIzol rea-
gent (Invitrogen). To assess mRNA expression, semiquantita-
tive RT-PCR and quantitative real-time PCRwere performed as
described previously (24). The generated cDNA was amplified
by using primers for human bid, bim, bik, bnip3L, gapdh (23),
bcl-gS (5-AAGGCCACGTGCCTGTAGC-3 and 5-CCCTG-
GATGCTGGTGTCAAC-3), puma (5-ACGACCTCAACG-
CACAGTACG-3 and 5-TGGGTAAGGGCAGGAGTCC-
3), tef (5-TGGTCCTGAAGAAGCTGATGG-3 and 5-TCC-
AGGTCCATGTACTCCAGG-3), andmouse dbp (5-GCGC-
GGCCTGTGAGCGACAGGA-3 and 5-TCACAGGGCCC-
CGTGCTGGGC-3).
Western Blot Analysis—Protein expression was determined
by Western blotting as described previously (25). Proteins
(30–60 g) were separated on a 12% polyacrylamide gel and
transferred to nitrocellulose. Blotswere blockedwith 3%bovine
serumalbumin and incubatedwith rabbit anti-Bcl-g antibodies,
which recognize both long and short isoforms (Abgent, San
Diego, CA), or mouse anti-FLAG and anti--tubulin (both
from Sigma) antibodies and then incubated with goat anti-rab-
bit or anti-mouse antibodies conjugated to alkaline phospha-
tase (Sigma). Bound antibody was detected by a chemilumines-
cence system (Applied Biosystems, Foster City, CA).
Gene Silencing—Cells were transfected with a 100 nM solu-
tion of a pool of four SMARTselectionTM-designed siRNA
duplexes specific for TEF, for all splicing variants of the bcl-g
gene, orwith a similar pool of irrelevant siRNAduplexes (Dhar-
macon, Chicago, IL) by using Lipofectamine 2000 (Invitrogen).
After 24 h of transfection, cells were incubated in the pres-
ence or in the absence of 80 M etoposide, and 24 h later,
transfected cells were analyzed for both bcl-gS mRNA
expression and apoptosis.
Transfections and Gene Reporter Assays—A genomic PCR
fragment from the promoter region of bcl-gS (413 bp) was
cloned into KpnI and HindIII sites of the pGL2-basic luciferase
reporter vector (Promega Corp., Madison,WI). The authentic-
ity of the construct was confirmed by sequencing. HEK293T
cells were cotransfected with 1 g of the promoter-containing
pGL2 construct, 1 g of TEF, DBP, HLF, or NFIL3 cDNAs
cloned into FLAG-containing pcDNA3 expression vector, and
20 ng of pRSV--gal by lipofection using Superfect (Qiagen).
When indicated, cells were cotransfected with pGL2-bcl-gS
promoter and a combination of both TEF and a truncated iso-
form of DBP (tDBP). 24 h after transfection, cell extracts were
prepared and analyzed for the relative luciferase activity by a
dual-light reporter gene assay system (Applied Biosystems).
Results were normalized for transfection efficiency with values
obtained with pRSV--gal. PCR site-directed mutagenesis of
the PAR bZIP consensus site at position13 in the bcl-gS pro-
moter was carried out by an overlap extension method (26).
The following primers were used to generate two DNA frag-
ments having overlapping ends (changed nucleotides are
underlined): sense, 5-TCTGCCCATGTGGCTGGGGAGGT-
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These fragments were then combined, allowing the 3 over-
lap of each strand to serve as a primer for the 3 extension of the
complementary strand. The bcl-gS promoter DNA inserts were
sequenced to verify the mutations. Transfection of cells with
the pcDNA3 vector containing FLAG-tagged TEF or tDBP or
with the vector alone (2 g each) was performed using Lipo-
fectamine 2000.
In some experiments, NTERA2 cells were cotransfectedwith
1 g of TEF orNFIL3 cDNAs and 0.2 g of a green fluorescent
protein (GFP)-containing vector (Genscript, Piscataway, NJ) by
using Lipofectamine 2000. After 24 h of transfection, GFP-pos-
itive cells were selected by a cell sorter (BDBiosciences, Heidel-
berg, Germany) and cultured for another 24-h period. These
cells were then subjected to gene expression analyses.
RESULTS
PAR bZIP Proteins Promote the Expression of a BH3-only
Gene—To assess whether PAR bZIP transcription factors were
able to regulate the expression of BH3-only genes, we first
looked for consensus sequences within the promoter regions of
these genes and found that bcl-gS contains a putative binding
sequence located 13 bases upstream from the transcription
start site (Fig. 1A). To study the functionality of this sequence,
HEK293T cells were cotransfected with a promoter fragment
from the bcl-gS gene cloned into a luciferase reporter vector and
each of the PAR bZIP genes inserted into a FLAG-containing
expression vector (pcDNA3-FLAG). As shown in Fig. 1B, TEF
increased luciferase activity more than 35-fold. DBP also acti-
vated the bcl-gS promoter (about 10-fold), whereas HLF had
no transcriptional activity. Interestingly, the transcriptional
repressor NFIL3, which shares the DNA binding site with PAR
bZIP proteins, down-regulated the basal activity of the bcl-gS
promoter (Fig. 1B). Furthermore, activation of the bcl-gS pro-
moter was abolished when a mutagenesis strategy changed
four bases within the PAR bZIP site. After transfection with
this construct, the TEF-mediated luciferase activity reached
the same value as that obtained with the promoterless vector
(Fig. 1C).
To directly prove the binding of PAR bZIP proteins to the
bcl-gS promoter, HEK293T cells were transfected with FLAG-
tagged HLF, DBP, TEF, and NFIL3 (Fig. 2A), and then nuclear
extracts were incubated with a radiolabeled probe from the
bcl-gS promoter and subjected to EMSA. In all cases, we
detected a protein-DNAbinding complex thatwas supershifted
in the presence of anti-FLAG antibodies (Fig. 2B).
Next, we studied the expression of bcl-gS in a number of
tumor cell lines and found the highestmRNAand protein levels
in NTERA2 and 2102Ep embryonal cancer cells (Fig. 3, A, and
B). Additionally, tefmRNAwas detected in these cells as well as
in RT112 and HCT116 (data not shown). To confirm the TEF-
dependent transcription of bcl-gS, NTERA2 cells were cotrans-
fected with TEF and a GFP-containing vector, and then the
GFP-positive cell population was sorted and analyzed for
expression of BH3-only genes by real-time RT-PCR. As shown
in Fig. 3C, TEF promoted a 5-fold induction of bcl-gS mRNA
levels when compared with empty vector-transfected cells,
whereas other BH3-only genes did not show significant varia-
tions in response to TEF. Consistent with our previous data,
NFIL3 down-regulated bcl-gS.
Recently, it has been described that p53 induces bcl-g (no
variant specified) in Saos cells (27). To assess whether p53 was
able tomodify theTEF-mediated expression of bcl-gS, we trans-
fected p53-deficient and wild type HCT116 cells with
pcDNA3-FLAG-TEF and then analyzed the expression of
bcl-gS by RT-PCR. Western blot analyses revealed the levels of
the transfected protein (Fig. 3D). As shown in Fig. 3D, HCT116
express no or very little constitutive levels of bcl-gS, which are
significantly increased in response to TEF regardless of the
presence of p53. Thus, TEF was able to up-regulate bcl-gS in a
p53-independent manner, although no significant apoptotic
response was observed (data not shown).
FIGURE 1. PAR bZIP proteins transactivate the bcl-gS gene. A, scheme of a
bcl-gS promoter fragment cloned upstream of the luciferase gene showing
the sequence of the PAR bZIP site. B, HEK293T cells were cotransfectedwith a
luciferase reporter vector containing the promoter region of bcl-gS and with
DBP, HLF, TEF, or NFIL3. Following 24 h of transfection, cell extracts were
prepared and analyzed for the relative luciferase activity. Cont., control. C, a
reporter vector containingwild typeormutantPARbZIP sites (themutant site
ismarkedwith an x) was introduced intoHEK293T cells, and luciferase activity
in response to TEF was determined after 24 h. The first two bars represent the
activity of the promoterless vector in the absence or in the presence of TEF.
Results were normalized for transfection efficiencywith values obtainedwith
pRSV--gal. All data points represent themeans S.D. of three independent
experiments.
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tDBP Functions as a Competitive Inhibitor of TEF—Gene
expressionanalysesbyRT-PCRinmouse tissues revealed thepres-
ence of a shorter (truncated) form ofDBP (tDBP) in the liver (Fig.
4B) that retains the PAR bZIP region but lacks the transactivation
domain (Fig. 4,A andC). A similar study inmore than 30 human
cell lines failed to detect a tDBP-like isoform but identified two
frameshift deletions that created premature stop codons, which
are predicted to result in the production of truncated proteins
lacking the PAR bZIP region and all or part of the transactiva-
tion domain (Fig. 4A). Fig. 4C shows that tDBP gives rise to a
shorter protein of the expected size. Consistently, EMSAexper-
iments demonstrated that tDBP, as well as DBP and TEF, binds
specifically to a probe from the bcl-gS promoter containing the
PAR bZIP binding site (Fig. 4D). The bZIP sequence contains the
DNA binding and protein dimerization domains. Thus, tDBP
couldact as anon-functional competitorofTEF that is able tobind
DNA and to dimerize with itself and with other PAR bZIP pro-
teins. To test this hypothesis, we cotransfected HEK293T cells
with pcDNA3-FLAG-TEF and increasing amounts of
pcDNA3-Myc-tDBP. As shown in Fig. 5A, tDBP dimerizes with
TEF to form heterodimers that bind to a consensus sequence
from the bcl-gS promoter. Both anti-FLAG and anti-Myc anti-
bodies confirmed the specificity of the protein-DNA binding
complexes. A similar approach was used to analyze the tran-
scriptional activity of TEF-tDBP heterodimers. Cells were
cotransfected with TEF, tDBP, and a vector containing the
luciferase gene driven by the bcl-gS promoter. The luciferase
activity was progressively down-regulated in the presence of
increasing amounts of tDBP (Fig. 5B). To further confirm the
blocking activity of tDBP, we determined the endogenous
expression of bcl-gS in HCT116 cells cotransfected with TEF
and tDBP. As shown in Fig. 5C, both proteins were coexpressed
in these cells following transfection. Consistent with our previ-
ous results, TEF up-regulated themRNA levels of bcl-gS, which
were significantly reduced (about 3-fold) in the presence of
tDBP (Fig. 5C and data not shown). These data indicate that
tDBP is a convenient molecular tool to study the TEF-bcl-gS
transcriptional pathway.
Chemotherapy Promotes Activation of the TEF-bcl-gS Tran-
scriptional Pathway—BH3-only proteins may be up-regulated
after treatment with chemotherapy, contributing to the apo-
ptotic response of the cell. Thus, we asked whether the TEF-
bcl-gS transcriptional pathway was activated by chemothera-
peutic agents. HCT116 cells were treated with increasing
concentrations of etoposide or cisplatin, and the endogenous
expression of bcl-gS was determined by real-time quantitative
PCR (Fig. 6A). Both treatments provoked at least a 4-fold induc-
tion of bcl-gS mRNA levels when compared with untreated
cells. The highest inductions were obtained with 40 M etopo-
side (12-fold) andwith 5M cisplatin (about 10-fold). However,
no variation in the levels of tef mRNA was observed (data not
shown). To confirm that chemotherapeutic agents activated
FIGURE 2. Binding of PAR bZIP proteins to the promoter of bcl-gS.
A, HEK293T cells were transfected with FLAG-tagged PAR bZIP cDNAs, and
theprotein expressionwas analyzedbyWesternblotwith anti-FLAGantibod-
ies. The levels of -tubulin were determined to assure equal loading. B,
nuclear extracts from transfected cells were obtained and analyzed for the
formationofprotein-DNAbindingcomplexesbyEMSA.Anti-FLAGantibodies
were used to show the specific binding of PAR bZIP and NFIL3 proteins. C,
control.
FIGURE 3. TEF induces the expression of bcl-gS in tumor cells. A, total RNA
was obtained from a number of cancer cell lines and analyzed for bcl-gS
expression levels by semiquantitative RT-PCR. gapdh mRNA was used as an
amplification control. B, cell lysates were subjected to Western blotting to
determine the expression of Bcl-gS protein. The levels of -tubulin were
determined to assure equal loading. C, NTERA2 cells were transfected with
TEForNFIL3 andaGFP-containingvector. Following24hof incubation, trans-
fected cells were sorted, cultured for another 24-h period, and analyzed for
expression of BH3-only genes by real-time quantitative PCR. Data are shown
as fold induction when compared with cells transfected with the empty vec-
tor. All data points represent the means S.D. of three independent experi-
ments. D, HCT116 cells null for the p53 alleles (/) or containing wild type
p53 (/) were transfected with TEF cDNA fused to the FLAG epitope
sequence and then analyzed after an overall culture time of 48 h for bcl-gS
expression by semiquantitative RT-PCR. Transfection efficiency was deter-
mined by Western blot with anti-FLAG antibodies. C, control.
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TEF, we analyzed the binding of this transcription factor to the
consensus site in the bcl-gS promoter by EMSA. As shown in
Fig. 6B, both etoposide and cisplatin increased the formation of
a protein-DNA complex in HCT116 cells. To detect the pres-
ence of endogenous TEF in this binding complex, we generated
a polyclonal anti-TEF antibody that detected a single protein of
the right size by Western blot analysis (Fig. 6C). This antibody
partly supershifted the protein-DNA complex, confirming that
TEF binds to the bcl-gS promoter in response to chemotherapy.
A more direct way to demonstrate that TEF mediates the che-
motherapy-induced transactivation of the bcl-gS gene is to
block the transcriptional activity of TEF. HCT116 cells were
transfectedwith either an empty vector or a FLAG-tagged tDBP
(Fig. 6D) and then cultured in the presence or in the absence of
etoposide. After 24 h of treatment, the etoposide-dependent
induction of bcl-gS mRNA was virtually blocked in tDBP-ex-
pressing cells (Fig. 6E). Quantification of the histone-associated
DNA fragments present in the cytosol, a feature of apoptosis,
demonstrated that the level of apoptosis following treatment
with etoposide decreased from 23% in control cells to 13% in
tDBP-expressing cells (Fig. 6E). To further confirm the rele-
vance of TEF in the chemotherapy-induced expression of bcl-
gS, we used an RNA interference approach to deplete cells of
endogenous TEF. Specific siRNA significantly reduced the TEF
mRNA levels and impaired the up-regulation of bcl-gS (Fig. 6F).
Furthermore, this interference strategy promoted a decrease in
apoptotic cell death as assessed by quantification of the histone-
associated DNA fragments (Fig. 6F) and annexin V binding
(Fig. 6G). Blockade of bcl-gS expression gave similar results. A
representative experiment is shown in Fig. 6H. Specific siRNA
impaired the etoposide-induced expression of bcl-gS mRNA
and gave rise to reduced levels of apoptotic cell death (from28%
to 14%) after treatment with etoposide. This result shows the
relevance of bcl-gS in chemotherapy-induced apoptosis.
DISCUSSION
BH3-only proteins are essential for the appropriate execu-
tion of apoptotic cell death. Thus, understanding the regulation
of BH3-only genes is necessary to gain insight into the mecha-
nisms of response to apoptotic stimuli. We have identified a
DNAbinding site for PARbZIPproteins in the promoter region
FIGURE 4. A truncated isoform of DBP lacking the transactivation
domain,binds to thebcl-gSpromoter.A, schemeof theopen reading frame
of DBP isoforms showing the position of functional domains. TAD, transacti-
vation domain. The arrowheads represent splice junctions, and dotted lines
the truncated sequence. B, RNA from mouse brain (B), lung (L), spleen (S),
thymus (Th), and testis (T) was analyzed by RT-PCR with dbp-specific primers.
Note the presence of a shorter band (tDBP) in the liver. C, to assure the proper
expression of TAD-defectiveDBP (tDBP), HEK293T cells were transfectedwith
tDBP cDNA fused to FLAG, and then cell lysates were analyzed by Western
blot with anti-FLAG antibodies. FLAG-tagged wild type DBP as well as the
empty vector were also included as size and specificity controls. D, HEK293T
cells were transfected with FLAG-TEF, FLAG-DBP, or FLAG-tDBP, and the for-
mation of protein-DNA binding complexes was determined by EMSA using a
radiolabeled probe from the bcl-gS promoter containing the PAR bZIP site.
Anti-FLAG antibodies were used to show the specific binding of transfected
proteins.
FIGURE 5. tDBP down-regulates the expression of bcl-gS. A, radiolabeled
probecontaining thePARbZIP siteof thebcl-gSpromoterwas incubatedwith
nuclear lysates from HEK293T cells transfected with FLAG-tagged TEF, Myc-
tagged tDBP, or both, and the formation of binding complexes was analyzed
by EMSA. Anti-FLAG or anti-Myc antibodies were used to show the specific
binding of overexpressed proteins. B, HEK293T cells were transfected with a
luciferase reporter vector containing the bcl-gS promoter in the presence of
TEF, tDBP, or both. Following 24 h of transfection, cell extracts were prepared
and analyzed for the relative luciferase activity. Results were normalized for
transfection efficiency with values obtained with pRSV--gal. C, HCT116 cells
were transfected with TEF or TEF plus tDBP (both tagged with the FLAG
epitope), and the expression of the overexpressed proteins was determined
by Western blot with anti-FLAG. Transfected cells were analyzed for the
expression of bcl-gS mRNA by semiquantitative RT-PCR. gapdh mRNA was
included as an amplification control. All histograms represent the means 
S.D. of triplicate analyses.
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of bcl-gS, a BH3-only gene. We also found that TEF promoted
the strongest induction. TEF has been shown to induce the
expression of thyroid-stimulating hormone  (6), pyridoxal
kinase, an enzyme involved in the activation of vitamin B6 (8),
telokin, a smooth muscle-restricted protein (28), and the
LMO2 transcription factor (29). More recently, TEF has been
associated with down-regulation of the common  chain of
cytokine receptors, but no transcriptional mechanism was
defined (30). Although this transcription factor is expressed in
the pituitary gland during embryonic development, it appears
in several tissues in themature organism, including brain, lung,
liver, spleen, and kidney (7). We have determined the expres-
sion of TEFmRNA in NTERA2, 2102Ep, HCT116, and RT112
cells. However, we were unable to clearly detect the endoge-
nous proteinwith our polyclonal anti-TEF antibody,most likely
because of the low affinity of this primary antibody, as it readily
revealed the overexpressed protein in transfected cells. We
determined that the highest expres-
sion levels of bcl-gS were found in
NTERA2 and 2102Ep, which are
testicular embryonal carcinoma
cells. Consistently, bcl-gS mRNA
has been found only in testis (16).
Overexpression of Bcl-gS in COS-7
cells induces apoptosis, which is
suppressed by coexpression of anti-
apoptotic Bcl-xL protein (16). We
have observed that transfection of
HCT116 and NTERA2 cells with
TEF promoted the expression of
bcl-gS but had no effect on cell sur-
vival. One possible explanation for
these apparently contradictory
results may be in the endogenous
levels of Bcl-gS, which are presum-
ably higher in cells transfected with
this gene than in cells overexpress-
ing its transcription factor. Alterna-
tively, the levels of Bcl-2 or Bcl-xL in
the different cell lines used in both
experiments may determine the cell
fate in response to Bcl-gS overexpres-
sion, as both anti-apoptotic proteins
counteract the action of BH3-only
family members (12, 31, 32).
We also identified a splicing vari-
ant of DBP (tDBP) in mouse liver
that retains theDNAbinding capac-
ity but has lost the transactivation
domain. TEF and DBP bind the
same DNA sequence (33) and form
heterodimers (6). Consistently, we
showed that tDBP competes with
TEF for binding to the bcl-gS pro-
moter and counteracts the TEF-me-
diated induction of endogenous bcl-
gS. Although we use tDBP here as a
convenient molecular tool for the
study of TEF-bcl-gS transcriptional pathway, it may be that this
or a similar truncated protein in humannormal or tumor cells is
acting as a regulator of TEF and other PAR bZIP proteins.
Splice variants of transcription factors involved in the expres-
sion of apoptosis regulators have been previously described. To
this end, a naturally occurring repressor isoform of Stat3 has
been shown to be coexpressed with the activator Stat3 in a
variety of cell types including leukemia cells (34). This variant
inhibits the transactivation potential of Stat3 andmay interfere
with the anti-apoptotic activity of this transcription factor. In
addition, p73 gene generates a truncated isoform that lacks the
transactivation domain, frequently overexpressed in human
cancers (35). This variant acts as a potent dominant inhibitor of
wild type p53 and transactivation-competent p73, blocking
their apoptotic response.
Chemotherapeutic agents have been shown to promote apo-
ptosis in numerous cell systems, including cancer cells, and
FIGURE 6. Chemotherapy regulates the TEF-bcl-gS transcriptional pathway. A, HCT116 cells were treated
with the indicated concentrations of etoposide (Eto) or cisplatin (Cis). After 24 h, total RNA was obtained and
analyzed for bcl-gS mRNA levels by real-time quantitative PCR. Data points represent the means  S.D. of
triplicate experiments. B, formation of protein-DNAbinding complexes in chemotherapy-treatedHCT116 cells
was determined by EMSA with a PAR bZIP site-containing probe from the bcl-gS promoter. An autoradiograh
of the EMSA revealed the TEF-DNA complex and a nonspecific band underneath this complex in lane 2. Poly-
clonal anti-TEF and irrelevant anti-Stat3 antibodies were used to show the specific binding of TEF. The arrow-
head indicates the position of the supershifted TEF-DNA complex. C, the specificity of the newly generated
mouse anti-TEF antibody was analyzed by Western blotting using extracts from cells transfected with the
emptyvector (C) orwithTEF.D, HCT116cellswere transfectedwithempty vector or FLAG-tagged tDBP, and the
overexpressedproteinwasdetectedbyWesternblotwith anti-FLAG. E, tDBP-expressing cellswere cultured for
24 h in the presence or in the absence of 80M etoposide, and themRNA levels of bcl-gSwere determined by
semiquantitative RT-PCR. F, HCT116 cells transfected with irrelevant (C) or tef-specific siRNA duplexes were
treatedwith 80M etoposide, and after 24 h, the expression of tef and bcl-gSmRNAwas analyzed.G, apoptosis
following treatment with etoposide was determined by flow cytometry with fluorescein isothiocyanate-la-
beled annexin V.H, cells were transfectedwith bcl-gS-specific siRNAduplexes and treated as in F. gapdhmRNA
was included as an amplification control. Numbers under the figures indicate the level of apoptosis as deter-
mined by a quantitative enzyme-immunoassay method in a representative experiment.
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BH3-only proteins play an essential role inmediating this proc-
ess. In line with this, paclitaxel has been recently described to
induce apoptosis in vitro and in tumors in vivo through a Bim-
dependent mechanism (20). In this model, inactivation of Bim
conferred resistance of cancer cells to paclitaxel. Other BH3-
only proteins such as Noxa, Puma, Bik, Bid, and Hrk have also
been associated with sensitivity to chemotherapy-induced apo-
ptosis (36–38). Consistent with this, we found that etoposide
and cisplatin, two commonly used chemotherapeutic agents,
activated the TEF-bcl-gS transcriptional pathway. Further-
more, tDBP or siRNA duplexes specific for all splicing variants
of the bcl-g gene efficiently reduced the levels of bcl-gS in
response to chemotherapy and partly blocked apoptosis, indi-
cating a significant participation of this pathway in chemother-
apy-induced apoptosis. Based on these data, TEF-bcl-gS may
participate in a regulatory network that controls the apoptotic
response to chemotherapeutic agents.
Together, this study shows a novel role for PAR bZIP pro-
teins in the transcriptional regulation of BH3-only genes,
mainly bcl-gS, and supports that this pathway can be activated
by chemotherapeutic agents in cancer cells, thus contributing
to the apoptotic response to chemotherapy. Further studies will
need to deepen the understanding of the physiological rele-
vance of this transcriptional pathway in normal and cancer
cells. It will also be of interest to find other targets of PAR bZIP
proteins that may be involved in apoptosis in different cell
systems.
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